Joint detection serum marker for early diagnosis of lung adenocarcinoma and application of joint detection serum marker

Abstract

The invention discloses a joint detection serum marker for early diagnosis of lung adenocarcinoma, comprising IgM autoantibodies of TSHR, ERBB2, Survivin, PIK3CA and JAK2. An ELISA serum detection kit is prepared by using a specific protein corresponding to the joint detection serum marker. The joint detection serum marker plays an important role in improving the sensitivity, specificity and accuracy of early diagnosis of lung adenocarcinoma. Meanwhile, the joint detection serum marker is combined with a CEA serum marker to construct a diagnosis model, and a serological detection method which is high in sensitivity, strong in specificity, low in cost and capable of assisting clinical diagnosis of lung adenocarcinoma is provided.

Description

technical field [0001] The invention belongs to the technical field of biomedical detection, and in particular relates to a combined detection serum marker that can be used for early diagnosis of lung adenocarcinoma and its application. Background technique [0002] In 2020, according to statistics, there will be 2.2 million new cases of lung cancer and 1.8 million deaths, accounting for 11.4% and 18.0% of all cancers respectively. It is the second most common cancer in the world with the highest mortality rate. Lung adenocarcinoma, as the most common histological subtype of non-small cell lung cancer, accounts for about 40% of lung malignancies, and mostly occurs in women and non-smokers. A large number of studies have shown that the 5-year disease-free survival rate of patients with adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) can be close to 100% if they undergo radical surgery. It can be seen that early diagnosis and timely and effective trea...

Images